Piper Sandler Maintains Overweight on Century Therapeutics, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Century Therapeutics (NASDAQ:IPSC) and raised the price target from $9 to $12.
June 17, 2024 | 11:46 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained an Overweight rating on Century Therapeutics and increased the price target from $9 to $12, indicating a positive outlook.
The increase in price target from $9 to $12 by a reputable analyst suggests a positive outlook for Century Therapeutics, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100